Financials Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-06-14 EDT 5-day change 1st Jan Change
298.6 USD +0.04% Intraday chart for Amgen Inc. -2.10% +3.68%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 143,240 133,852 126,718 140,139 154,142 160,190 - -
Enterprise Value (EV) 1 164,232 156,191 151,990 169,779 207,811 208,791 203,801 198,611
P/E ratio 18.7 x 18.7 x 21.9 x 21.7 x 23.1 x 37.6 x 24.2 x 21.9 x
Yield 2.41% 2.78% 3.13% 2.95% 2.96% 3.09% 3.33% 3.55%
Capitalization / Revenue 6.13 x 5.26 x 4.88 x 5.32 x 5.47 x 4.85 x 4.72 x 4.61 x
EV / Revenue 7.03 x 6.14 x 5.85 x 6.45 x 7.37 x 6.33 x 6 x 5.72 x
EV / EBITDA 12.3 x 9.8 x 9.61 x 10.5 x 11.9 x 11.2 x 10.6 x 10.2 x
EV / FCF 19.2 x 15.8 x 18.1 x 19.3 x 28.2 x 13.3 x 15.8 x 15.1 x
FCF Yield 5.2% 6.33% 5.51% 5.17% 3.54% 7.52% 6.32% 6.62%
Price to Book 14.7 x 14.1 x 18.7 x 38.3 x 24.7 x 28.3 x 22.9 x 18.4 x
Nbr of stocks (in thousands) 594,184 582,169 563,266 533,579 535,178 536,435 - -
Reference price 2 241.1 229.9 225.0 262.6 288.0 298.6 298.6 298.6
Announcement Date 20-01-30 21-02-02 22-02-07 23-01-31 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 23,362 25,424 25,979 26,323 28,190 32,998 33,967 34,713
EBITDA 1 13,363 15,935 15,822 16,178 17,470 18,633 19,156 19,451
EBIT 1 11,157 12,334 12,424 12,761 13,399 14,814 15,563 15,930
Operating Margin 47.76% 48.51% 47.82% 48.48% 47.53% 44.89% 45.82% 45.89%
Earnings before Tax (EBT) 1 9,138 8,133 6,701 7,346 7,855 4,502 7,756 7,867
Net income 1 7,842 7,264 5,893 6,552 6,717 4,109 6,208 6,876
Net margin 33.57% 28.57% 22.68% 24.89% 23.83% 12.45% 18.28% 19.81%
EPS 2 12.88 12.31 10.28 12.11 12.49 7.932 12.34 13.62
Free Cash Flow 1 8,532 9,889 8,381 8,785 7,359 15,699 12,875 13,143
FCF margin 36.52% 38.9% 32.26% 33.37% 26.11% 47.58% 37.9% 37.86%
FCF Conversion (EBITDA) 63.85% 62.06% 52.97% 54.3% 42.12% 84.26% 67.21% 67.57%
FCF Conversion (Net income) 108.8% 136.14% 142.22% 134.08% 109.56% 382.1% 207.38% 191.14%
Dividend per Share 2 5.800 6.400 7.040 7.760 8.520 9.222 9.956 10.59
Announcement Date 20-01-30 21-02-02 22-02-07 23-01-31 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 6,846 6,238 6,594 6,652 6,839 6,105 6,986 6,903 8,196 7,447 8,319 8,433 8,808 8,099 8,592
EBITDA 1 3,849 3,981 4,163 4,114 3,920 3,721 4,411 4,298 5,040 4,477 5,147 5,302 5,053 - -
EBIT 1 2,997 3,140 3,335 3,277 3,009 2,821 3,515 3,403 3,660 3,078 3,793 3,921 4,059 3,694 4,001
Operating Margin 43.78% 50.34% 50.58% 49.26% 44% 46.21% 50.31% 49.3% 44.66% 41.33% 45.59% 46.49% 46.08% 45.61% 46.57%
Earnings before Tax (EBT) 1 2,131 1,675 1,531 2,392 1,748 3,442 1,614 1,947 852 -68 1,397 1,418 1,667 - -
Net income 1 1,899 1,476 1,317 2,143 1,616 2,841 1,379 1,730 767 -113 1,221 1,357 1,241 1,039 1,365
Net margin 27.74% 23.66% 19.97% 32.22% 23.63% 46.54% 19.74% 25.06% 9.36% -1.52% 14.68% 16.09% 14.09% 12.83% 15.89%
EPS 2 3.360 2.680 2.450 3.980 3.000 5.280 2.570 3.220 1.420 -0.2100 2.539 2.739 2.503 3.105 3.740
Dividend per Share 2 1.760 1.940 1.940 1.940 1.940 2.130 2.130 2.130 2.130 2.250 2.293 2.293 2.293 - -
Announcement Date 22-02-07 22-04-27 22-08-04 22-11-03 23-01-31 23-04-27 23-08-03 23-10-31 24-02-06 24-05-02 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 20,992 22,339 25,272 29,640 53,669 48,600 43,611 38,421
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.571 x 1.402 x 1.597 x 1.832 x 3.072 x 2.608 x 2.277 x 1.975 x
Free Cash Flow 1 8,532 9,889 8,381 8,785 7,359 15,699 12,875 13,143
ROE (net income / shareholders' equity) 81.4% 103% 122% 185% 203% 156% 156% 153%
ROA (Net income/ Total Assets) 14.3% 16% 15.8% 15.2% 12.4% 6.32% 7.8% 9.12%
Assets 1 54,778 45,481 37,328 43,230 54,315 65,003 79,639 75,393
Book Value Per Share 2 16.40 16.30 12.00 6.860 11.60 10.60 13.10 16.20
Cash Flow per Share 2 15.00 17.80 16.20 18.00 15.70 20.70 21.30 25.30
Capex 1 618 608 880 936 1,112 1,069 1,051 1,150
Capex / Sales 2.65% 2.39% 3.39% 3.56% 3.94% 3.24% 3.09% 3.31%
Announcement Date 20-01-30 21-02-02 22-02-07 23-01-31 24-02-06 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
298.6 USD
Average target price
316.4 USD
Spread / Average Target
+5.97%
Consensus